Zimmer Biomet was cited as an example of a company expected to improve its cost structure at key U.S. manufacturing facilities. The company is wrestling with a recent recal l of implantable spine fusion and bone growth stimulators and a warning letter for practices at its Warsaw, Indiana north campus plant. Moody's cautioned that Zimmer Biomet will have a limited capacity to deviate from prioritization of debt reduction from free cash flow.